论文部分内容阅读
目的：探讨维甲酸联合亚砷酸治疗初治急性早幼粒细胞白血病的临床疗效。方法回顾性的分析我院2012年1月~2015年8月初治的急性早幼粒细胞白血病病例，共49例。依据诱导方案不同，分为维甲酸组及维甲酸联合亚砷酸组，后继给予3~4疗程蒽环类药物联合标准剂量阿糖胞苷巩固治疗。分别观察两组的疗效及不良反应。结果维甲酸组与联合组诱导缓解治疗完全缓解率分别为90%、100%，达中位缓解时间分别为29d、28d，缓解率高于维甲酸组，差异无统计学意义（>0.05）。分化综合征的发生率分别为40%、42%，差异无统计学意义（>0.05），髓内复发率分别为18%、31%；髓外复发率分别为9%、10%；3个周期巩固治疗后融合基因转阴率分别为68%和89%。结论对急性早幼粒细胞白血病患者采用维甲酸联合亚砷酸进行诱导治疗，完全缓解率高，治疗过程中无明显的增加不良反应发生率。“,”Objective To evaluate clinical efficacy of all-trans retinoic acid incombination with arsenic trioxide therapy for newly diagnosed acute promyelocytic leukemia APL patients.Methods The clinical Efficacy and adverse reactions of 49 cases of APL treated from January 2012 to August 2015 in our departement were analysed retrospectively,Depending on the different induction regimens the cases is divided into retinoic acid-induced group and retinoic acid combined arsenic trioxide group,Following the 3~4 give anthracycline treatment in combination with standard-dose cytarabine consolidation therapy.Results Retinoic acid group and the combination group after remission induction therapy complete remission rate of 90%,100%, reaching a median time of 29 days,respectively,28 days,remission rate in is higher in combinition group,the difference was not statistically significant ( >0.05).The differentiation syndrome incidence are 40%and 42%respectively,the difference has no statistically significant.Intramedullary relapse rates were 18%,31%;extramedullary relapse rate of 9%,10%,respectively;after three cycles of consolidation therapy fusion gene negative rate of 68%and 89%,respectively.Conclusion Patients with acute promyelocytic leukemia cells using retinoic acid and arsenic trioxide induction therapy has a higher complete remission rate,has no significant increase in incidence of adverse reactions.